Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

CONCLUSIONS: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.PMID:34644524 | DOI:10.18433/jpps31862

Source: J Pharm Pharm Sci - October 13, 2021 Category: Drugs & Pharmacology Authors: Takehiro Kawashiri Daisuke Kobayashi Mayako Uchida Shiori Hiromoto Masashi Inoue Hajime Ikeda Mizuki Inoue Takao Shimazoe Source Type: research